Hypertension affects the endocannabinoid system, which consists of (1) cannabinoid receptors (e.g., CB1), (2) endogenous cannabinoids represented by anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and (3) mechanisms terminating their activity including enzymes like fatty acid amide hydrolase (FAAH; degrades AEA) and monoacylglycerol lipase (MAGL; degrades 2-AG) and endocannabinoid membrane transporters (EMTs) [28]. Here, MGLL is linked to hypertensive disorder.